<DOC>
	<DOCNO>NCT02937168</DOCNO>
	<brief_summary>This exploratory study primary objective 1 ) establish PET/CT lung reliably distinguish healthy , non-asthmatic volunteer patient asthma eosinophilic phenotype 2 ) examine utility PET/CT demonstrate reslizumab produce reduction lung inflammation patient severe asthma eosinophilic phenotype .</brief_summary>
	<brief_title>An Imaging Study Using PET/CT Characterize Effect Intravenous Reslizumab Airway Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Females either surgically sterile , 2 year postmenopausal , negative pregnancy test screening Females childbearing potential ( surgically sterile 2 year postmenopausal ) , use medically accept method contraception agree continue use method duration study 5 month study drug administration . Subjects patient less 10pack year history smoking . Have previous diagnosis asthma . Patients take inhaled fluticasone dosage least 440 mcg daily , equivalent . The patient 's baseline asthma therapy must stable 30 day prior screen judge treat physician able continue without dosage change throughout study . Patients blood eosinophil level least 400/μL screen . Additional criterion apply , please contact investigator information Patients require treatment oral , intramuscular , iv corticosteroid within 6 week Part 1 baseline visit . Patients confound underlying lung disorder include limited : bronchiectasis , chronic obstructive pulmonary disorder , smoke ≥10 pack year history , pulmonary fibrosis , emphysema , cystic fibrosis , lung cancer . Patients diagnose diabetes mellitus . Patients pulmonary condition blood eosinophilia eosinophilic asthma Patients clinically meaningful comorbidity interfere study schedule procedure , compromise patient 's safety . Patients current smoker ( ie , smoke within last 12 month prior screen ) . Patients use systemic immunosuppressive , immunomodulating , biologic within 6 month prior screen . Patients previously receive antihuman interleukin5 ( antihIL5 ) mAb ( eg , reslizumab , mepolizumab [ Nucala® ] ) anti IL5 receptor mAb ( eg , benralizumab ) . Patients concurrent infection disease may preclude assessment active asthma . Patients history concurrent immunodeficiency ( human immunodeficiency virus acquire immunodeficiency syndrome congenital immunodeficiency ) . Patients active parasitic infection within 6 month prior screen . Patients disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) . Known hypersensitivity study drug FDG/contrast agent Treatment metformin . Compromised renal function Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>